Adaptimmune Therapeutics PLC (ADAP)
1.10
-0.10
(-8.33%)
USD |
NASDAQ |
May 17, 16:00
1.10
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Revenue (Annual): 60.28M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 60.28M |
| December 31, 2022 | 27.15M |
| December 31, 2021 | 6.149M |
| December 31, 2020 | 3.958M |
| December 31, 2019 | 1.122M |
| December 31, 2018 | 59.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 37.83M |
| December 31, 2016 | 14.20M |
| December 31, 2015 | 8.979M |
| June 30, 2015 | 9.871M |
| June 30, 2014 | 0.825M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
1.122M
Minimum
2019
60.28M
Maximum
2023
19.73M
Average
6.149M
Median
2021
Revenue (Annual) Benchmarks
| Biodexa Pharmaceuticals Plc | 0.4741M |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | 1.698M |
| TC BioPharm (Holdings) PLC | -- |
| Mereo BioPharma Group PLC | 10.00M |